HYPERFINE

Defining the Future of Life-Saving Diagnostics at the Point of Care

Corporate Presentation | June 8, 2022

Forward Looking Statements

This presentation includes forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance, the impact of COVID-19 or geo-political conflict such as the war in Ukraine, on our business and prospects for recovery, expense management, expectations for hiring, physician training and adoption, growth in our organization, market opportunity, commercial and international expansion, regulatory approvals, and product development are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the “Risk Factors” section of our 10-Q filed with the Securities and Exchange Commission on May 12, 2022.

Today, brain diagnostics are single point-in-time and delay the time from door to discharge.

Our mission is to **transform healthcare** by creating access to **life-saving diagnostics** and **actionable data at the patient bedside.**

HYPERFINE

The Hyperfine Ecosystem

Democratizing **Imaging**, **Sensing**, and **Guided Intervention** to cover the care continuum

Imaging
(FDA cleared)

Sensing
(in development)

Intervention
(exploratory)

A full ecosystem solution: Hardware, software, consumables and applications powered by artificial intelligence

HYPERFINE

Imaging, Sensing, and Guided Intervention are Large Markets Poised for Disruption



Imaging: Commercially Available
Hospitals, Outpatient

>100,000
Potential installation targets

Sensing: In Development
ICUs, Expanded Hospital, Surgical Centers, Outpatient, At-home

~4M
Potential unit sales

Guided Intervention: Longer-Term Opportunity
Hospitals and Health Systems

>50M
Potential image guided procedures

HYPERFINE

We are Transforming Medical Imaging with Swoop®

MRI 1.0
1980

MRI 2.0
1990

MRI 3.0
FDA Cleared 2020

HYPERFINE

Swoop® is the Next Generation of MRI

Patent protected noise cancellation system enables clinical-grade images

Portable low-field MRI

FDA Cleared in 2020

Reimbursed under existing imaging codes:
MRI Brain without Contrast: 70551

>140 issued patents worldwide;
>80 issued patents in the U.S.

Installed base of **85 units*** as of 1Q 2022 end

Clinical Applications including:

- ICU Follow-Up and Post-Operative
- Hydrocephalus and Pediatrics
- Stroke

*Installed base includes commercial system installations (which make up total revenue), grant fulfillment installations, and research unit installations

HYPERFINE

Swoop® Brings MRI to the Patient

Acute Care Settings

Intensive Care Units
and Operating Rooms

Global Health

- Swoop is designed to enable **rapid diagnoses and treatment** for patients regardless of income, resources, or location
- Produces **high-quality images at low magnetic field strength**, allowing clinicians to quickly scan, diagnose, and treat patients
- Wheeled **directly to a patient's bedside**, plugged into a **standard electrical wall outlet**, and **controlled by an iPad®**

HYPERFINE

Clinical & Workflow Benefits

HYPERFINE

Adverse events occur in **22-46%** **of cases** during transport

Numerous **challenges** with conventional MRI :

- High-cost limits accessibility
- Complex site requirements and upgrades
- Scheduling delays lead to longer length of stay
- Consumption of valuable personnel resources
- Risk of adverse events during transportation
- Maintaining connection to life support equipment

HYPERFINE

Hyperfine Workflow Benefits

Traditional MRI workflow (25.8 hours)





Hyperfine workflow (90 mins, 94% reduction in total workflow time)

HYPERFINE

Swoop Clinical Use Cases Today

Intensive Care Unit
- Acute Mental Status Change
- Ataxia
- Cerebral Edema
- Cerebrovascular Disease
- Cranial Neuropathy
- Extra Ventricular Drain Placement
- Follow-up Intracranial Hemorrhage
- Follow-up Ischemic Stroke
- Follow-up Hematoma
- Stroke
- Tumor Pre- and Post-Op

Emergency Department
- Blurred Vision
- Cranial Neuropathy
- Dizziness
- Headache
- Numbness
- Stroke
- Tingling
- Traumatic Brain Injury
- Vertigo
- Weakness



Rehabilitation Clinic
- Acute Mental Status Change
- Brain Injury After Fall
- Stroke Recovery

Outpatient
- Atrophy Monitoring
- Hydrocephalus (Shunt Check)
- Multiple Sclerosis

Pediatric
- Brain Volumetrics
- Hypoxic Ischemic Encephalopathy
- Hydrocephalus (Dx and Monitoring)
- Sports Injury
- Suspected Abuse

HYPERFINE

Clinical Validation of Hyperfine

> Game changer is a good way to put it […] being able to do the level of sophisticated imaging in an ICU that MRI can provide.''
>
> **Dr. Fady Charbel, MD, FAANS, FACS**

> Hyperfine provides me with an opportunity to acquire the information, to interpret the information, and to make a decision based on the information that's in front of me.''
>
> **Dr. Shahid Nimjee, MD, PhD, FAANS, FAHA**

> Portable MRI should be used to image any patients in ICUs in any [clinical] setting.''
>
> **Dr. Michael Schulder, MD, FAANS**

Over 40 conference presentations and publications discussing clinical benefits for:

Stroke | Hydrocephalus | Hematoma | Multiple sclerosis | Tumor resection



HYPERFINE

Recent Highlights:

Science Advances, April 2022:

Portable, Low-Field MRI Enables Highly Accessible and Dynamic Bedside Evaluation of Ischemic Stroke

- Imaged 50 confirmed acute ischemic stroke patients and accurately detected infarcts in 45/50 patients (90%); captured lesions as small as 4 mm

American Journal of Neuroradiology, April 2022:

Implementation of a Low-Field Portable MRI Scanner in a Resource-Constrained Environment: Our Experience in Malawi

- Acquired >260 brain scans; concluded use may lead to faster diagnosis and expedited treatment, including in comatose patients in the E.D. and bed-bound patients with sudden onset neurologic deficits

Nature Communications, August 2021:

Portable, Bedside, Low-Field Magnetic Resonance Imaging for Evaluation of Intracerebral Hemorrhage

- Imaged >140 patients and correctly identified ICH in over 80% of confirmed cases

14 Published Manuscripts Across Renowned Journals

HYPERFINE

Use Case: ICU

HYPERFINE

Patient Delays to Transfer in the ICU Creates Major Unnecessary Costs for Hospitals, is “Common and Costly”

Estimated $300/hr for delays, >$22,000/week for hospital (>$1M/year) for large academic center

Imaging capabilities of MRI, CT and Ultrasound **should be available 24/7/365** at all facilities.

In reality, patients can **wait more than 24 hrs for MRI availability**, resulting in cost for both the patient and the hospital, taking up an ICU bed.

If only there was a way to improve access to imaging…

HYPERFINE

Current ICU Imaging Workflow with Conventional MRI

Traditional MRI workflow can lead to **prolonged delays** in patient care and **higher resources consumption**



HYPERFINE

Improved ICU Imaging Workflow with Swoop

Portable MRI workflow enables **timely care** for earlier discharge by bringing brain imaging to the patient's bedside



HYPERFINE

Word from the Clinician

> Using the scanner in the ICU is an important use case. What Swoop can offer versus a conventional MRI is the **flexibility** and the usefulness of having it right there. It **favors time** in a situation when you need something acute.

Dr. Jennifer Moliterno-Gunel, Neurosurgeon
Yale University School of Medicine

HYPERFINE

Swoop’s Potential Benefits in the ICU

Reduced time to diagnosis

Swoop workflow is significantly faster than conventional MRI

Reduced patient care interruption

Transport time (2-3 hours) interrupts patient care and impacts staffing for entire ICU[1]

Reduced adverse events associated with patient transport

Adverse events occur in up to 46% of transported patients.

Reduced costs associated with length of stay

Shortening time to diagnosis, avoiding interruptions in care, and preventing adverse events

Optimized staffing in the ICU

Time consuming transport affects ICU staff: nurse, respiratory therapist, anesthesia, transport, and practitioner.

Reduced exposure to ionizing radiation

Ionizing radiation from CT used for serial follow-up scans = risk to patient and staff

1. Hyperfine, *Care Area - Acute Mental Status Change*, Page 1a

HYPERFINE

Use Case: Hydrocephalus

HYPERFINE

Pediatric Hydrocephalus Management is a Huge Problem

~400,000 hospital days, $2B in hospital charges in the US

Children with hydrocephalus need **life-long monitoring** and use a disproportionate number of hospital days and **resources**.[1, 2]



Children can receive **1-12 CTs[5] each year**, increasing their risk for radiation-associated malignancy[6]. Rapid MRI (T2 only) is preferred since it's radiation free but may not be available.

Any symptoms cause trips to hospital for a shunt check to ensure pressure on the brain remains normal. **50% of shunts fail in <2 years and 98% of shunts fail by year 10.**[2,3,4]

Swoop helps overcome existing workflow barriers to enable safe and timely imaging at the point of care for an improved patient experience.

1. https://thejns.org/focus/view/journals/neurosurg-focus/37/5/article-pE5.xml
2. https://www.gosh.nhs.uk/conditions-and-treatments/conditions-we-treat/ventriculomegaly/
3. https://www.hydroassoc.org/cerebral-shunt-malfunctions/
4. https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Hydrocephalus
5. https://link.springer.com/article/10.1007/s00381-019-04345-3
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166961/
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053664/
8. https://www.hydroassoc.org/powerful-facts/

HYPERFINE

Personal Story from the Hydrocephalus Association

> Received so many CT scans that we're waiting on a cancer diagnosis. **No radiation... Swoop is a parent's dream.**

HYPERFINE

Hydrocephalus Workflow Improvement with Swoop®

Traditional workflow results in delayed diagnosis and potential radiation exposure



Hyperfine allows children to be imaged sooner, next to their loved ones, **without radiation**

HYPERFINE

Hydrocephalus: Swoop's Potential from Early Cases

> Hyperfine is an excellent addition to the neurosurgery clinic for screening of hydrocephalus patients. The convenience for the patient, reduced scan time, and cost of the machine make this a device that should be considered for any neurosurgery clinic.

Jeff Leonard, MD
Chief of Neurosurgery

NATIONWIDE CHILDREN'S®
When your child needs a hospital, everything matters.



5 y/o presents to Neurosurgery clinic with headache. Swoop® scan performed in the clinic demonstrates ventricular catheter (without artifact from valve) along with enlarged ventricles – child admitted to hospital for shunt revision immediately, saving radiation and delay.

HYPERFINE

Use Case: Stroke

HYPERFINE

Hyperfine Provides Compelling Platform for Stroke Diagnosis

15 million people worldwide suffer a stroke annually

MRI scans are better at **detecting ischemic stroke damage** compared to CT scans

Stroke is the **2nd leading cause of death** globally

MRI use for stroke has been limited due to **lack of access** to this expensive equipment and experienced neuroradiologists to interpret the results.

87% strokes are ischemic strokes

Hyperfine offers an affordable MRI platform that can perform diffusion imaging for stroke diagnosis at the patient's bedside, images can be shared securely with neuroradiologists around the world

HYPERFINE

Stroke Diagnosis Confirmed

62-year-old male

Presented with new left sided weakness and tremor

HYPERFINE

Clinical Settings Growth

Today's use cases provide a sizeable opportunity and platform for growth.



HYPERFINE

Pipeline Opportunities

HYPERFINE

Innovative R&D Engine Designed to Expand Product Roadmap

Potential benefits:

- Improved usability
- Expanded Addressable Market
- Lower cost of goods
- Automated Stroke Detection

- Existing applications V1
- Potential future applications V2

- ICU
- Hydrocephalus
- Stroke
- C-spine
- Extremities
- Intra and Post Operative

HYPERFINE

Developing a Non-Invasive Brain Vital Sensor

Breakthrough technology designed to unlock access to blood flow and pressure

Non-Invasive

Non-invasive use on every patient to enable broader access and earlier diagnosis

Continuous Trend Analysis

Designed for continuous sensing to build trends for data-backed treatment

Easy to use

Designed to be easy to use for immediate, precise care

*The first medical device is being developed to aid in the diagnosis and management of brain disorders through the development of novel acoustic sensing techniques and innovative algorithms for measuring key metrics of brain health.

HYPERFINE

Brain-Sensing Clinical Opportunities

Intensive Care Unit

- Hydrocephalus
- Vasospasm
- Stroke
- Cerebral edema
- Traumatic Brain Injury
- Subarachnoid hemorrhage
- Suspected seizures
- Acute liver failure
- Altered mental status
- Brain tumors
- Sepsis

Operating Room

- Intraoperative monitoring/anesthesia
- Post surgical monitoring
- Thrombectomy
- Hematoma
- Stent thrombosis

Outpatient & At Home

- Shunts
- Epilepsy
- Tumor progression
- Concussion long-term effects
- Idiopathic intracranial hypertension
- Asymptomatic carotid stenosis
- Hypertension
- Obstructive sleep apnea
- Sickle cell anemia

Emergency Department

- Traumatic Brain Injury
- Stroke
- Seizures
- Triage for lumbar punctures
- Altered mental status
- Headaches
- Status epilepticus
- Cardiac arrest
- Hypertensive urgency and emergency

HYPERFINE

Financial Profile

HYPERFINE

1Q 2022 Financial Results & Total Installed Units

- **$1.509 million in 1Q 2022 total sales**
- Total sales increased by $1.2 million, or >400%, for the quarter ended March 31, 2022 compared to the corresponding prior-year period

TOTAL INSTALLED UNITS							
	2020	2021				2022	
		Q1	Q2	Q3	Q4	Q1	TOTAL
Commercial system installations*	4	5	7	4	7	11	38
Grant fulfillment installations	—	2	2	4	10	2	20
	4	**7**	**9**	**8**	**17**	**13**	**58**
Research units	15	2	2	3	3	2	27
Total Installed Units	**19**	**9**	**11**	**11**	**20**	**15**	**85**

Commercial system installations reflect device sales and subscription services through commercial agreements (commercial sales) or through research transfer agreements ("RTA") sales. Commercial sales are made to hospitals and other healthcare providers as direct sales of devices and software subscription services or through subscriptions for the use of the device and software. RTA sales represent the sale of Swoop units for research use purposes.

HYPERFINE

2022 Financial Guidance

- $10.0-$12.0 million in total revenue for full year 2022
- 50-60 commercial system installations in full year 2022





**2022 bar chart values reflect fiscal year financial guidance, not reported results*

HYPERFINE

Major Recent Accomplishments

- **April 2022:** Swoop® Demonstrates High Accuracy for Identification and Evaluation of Ischemic Stroke in Study Published by Science Advances
- **February 2022:** Appointed Chip Truwit, M.D. as Senior Medical Director
- **December 2021:** Closed Business Combination with HealthCor Catalio Acquisition Corp. and Liminal Sciences, Began Trading under the Ticker "HYPR" on the Nasdaq Global Market
- **December 2021**: Announced Expansion into Canadian Market with Medical Device License Issued by Health Canada
- **November 2021**: Received FDA Clearance for Deep Learning Portable MRI, Defining the Future of Life-Saving Diagnostics
- **September 2021**: Announced Receipt of Additional $3.3 Million Grant from Bill & Melinda Gates Foundation to Improve Access to Neonatal and Pediatric Brain Imaging in Low-Resource Settings Globally
- **September 2021**: Announced Plans for Global Expansion Starting with Launches in the UK and Pakistan
- **August 2021**: Swoop® Demonstrates High Accuracy for Detection of Brain Hemorrhage in Study Published in Nature Communications
- **July 2021**: Announced Definitive Agreement to be Listed on Nasdaq through a Business Combination with HealthCor Catalio Acquisition Corp.

HYPERFINE

incubatED

AuntMinnie.com
THE BEST OF RADIOLOGY
FINALIST

AuntMinnieEurope
THE BEST OF RADIOLOGY
WINNER



FROST & SULLIVAN
BEST
2020 PRACTICES
AWARD

FIERCE Biotech
FIERCE 15

2021
GOLD WINNER
MEDICAL DESIGN
EXCELLENCE AWARDS

FAST COMPANY
WORLD
CHANGING
IDEAS 2021

CES
INNOVATION
AWARDS
2021
HONOREE

HYPERFINE

Leadership Team

HYPERFINE

Management Team with Proven Track Record of Success

Dave Scott

Chief Executive Officer

Alok Gupta

Chief Financial Officer

Dr. Khan Siddiqui

Chief Strategy Officer & Chief Medical Officer

Tom Teisseyre

Chief Product Officer



Mark Hughes

VP, Hardware Engineering & Operations

Scott White

Chief Commercial Officer

Kyla Pavlina

Chief People Officer

Neela Paykel

General Counsel & Chief Compliance Officer

HYPERFINE

Thank You!


CARRERA
Hyperfine Swoop
The world's first
portable MRI system.
HYPERFINE
HYPR | Nasdaq Listed
Nasdaq
ILLIANT.
NETFLIX
THE LOST DAUGHTER

Appendix

HYPERFINE

Brain is the Largest MRI Market with Nearly 25% of MR Procedures

MR Procedure Mix, All Sites, by Percent, 2020



Distribution of MR Sites and Procedures, by Site Type, 2020



*Source: 2020 IMV MR Benchmark Report

HYPERFINE